- Home
- XERS vs GGN Comparison
XERS vs GGN Comparison
Compare XERS & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | GGN |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 965.6M | 877.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | XERS | GGN |
|---|---|---|
| Price | $5.47 | $5.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $10.43 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 532.7K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $28.65 | N/A |
| Revenue Next Year | $18.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $3.68 |
| 52 Week High | $10.08 | $5.88 |
Technical Indicators
Market Signals| Indicator | XERS | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 26.31 | 39.31 |
| Support Level | $4.30 | $5.14 |
| Resistance Level | $5.49 | $5.32 |
| Average True Range (ATR) | 0.34 | 0.12 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 3.62 | 0.00 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About GGN GAMCO Global Gold Natural Resources & Income Trust
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.